Skip to main content
SpringerLink
Log in

Daunorubicin

  • Chapter
Extravasation of Cytotoxic Agents

  • 933 Accesses

Abstract

1. Stop injection/infusion immediately

2. Get extravasation kit

3. Put on (sterile) gloves

4. Replace infusion lead or syringe with 5 ml disposable syringe and aspirate slowly as much as possible of the extravasated drug; Cave! do not exert pressure on extravasation area

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Original articles

  1. Lawrence HJ, Goodnight SH: Dimethyl sulfoxide and extravasation of anthracycline agents. Ann Intern Med 98: 1025, 1983.

    Article  PubMed  CAS  Google Scholar 

  2. Olver IN, Aisner J, Hament A, et al: A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation. J Clin Oncol 6: 1732–1735, 1988.

    PubMed  CAS  Google Scholar 

  3. Larson DL: What is the appropriate management of tissue extravasation by antitumor agents? Plast Reconstr Surg 75: 397–402, 1985.

    Article  PubMed  CAS  Google Scholar 

  4. Kappel B, Hindenburg AA, Taub RN: Treatment of anthracycline extravasation – a warning against the use of sodium bicarbonate. J Clin Oncol 5: 825–826, 1987.

    PubMed  CAS  Google Scholar 

  5. Jackson IT, Robinson DW: Severe tissue damage following accidental subcutaneous infusion of bicarbonate solution. Scot Med J 21: 200–201, 1976.

    PubMed  CAS  Google Scholar 

  6. Gaze NR: Tissue necrosis caused by commonly used intravenous infusions. Lancet 2: 417–419, 1978.

    Article  PubMed  CAS  Google Scholar 

  7. Dragon LH, Braine HG: Necrosis of the hand after daunorubicin infusion distal to an arteriovenous fistula. Ann Intern Med 91: 58–59, 1979.

    Article  PubMed  CAS  Google Scholar 

  8. Dührsen U, Heinrichs V, Beecken WD, et al: Local and systemic sequale of mediastinal daunorubicin extravasation in a patient with acute myelomonocytic leukemia. Ann Oncol 8: 1167–1169, 1997.

    Article  PubMed  Google Scholar 

  9. Langer SW, Sehested M, Jensen PB: Treatment of anthracycline extravasation with dexrazoxane. Clin Cancer Res 6: 3680–3686, 2000.

    PubMed  CAS  Google Scholar 

  10. Langer SW, Sehested M, Jensen PB: Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice Ann Oncol 123: 405–410, 2001.

    Article  Google Scholar 

Secondary literature

  1. Bertelli G: Prevention and management of extravasation of cytotoxic drugs. Drug Safety 12: 245–255, 1995.

    Article  PubMed  CAS  Google Scholar 

  2. Ignoffo RJ, Friedman MA: Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev 7: 17–27, 1980.

    Article  PubMed  CAS  Google Scholar 

  3. Schneider G: Paravasate von Zytostatika. Diagnostik und Therapie. Aina S. Schneider Verlag, 6th edition 1–17, 1999.

    Google Scholar 

  4. Krämer I: Onkologische Pharmazie. In: Jaehde U, Radziwill R, Mühlebach S, et al (eds) Lehrbuch der Klinischen Pharmazie. Wissenschaftliche Verlagsgesellschaft mbH, 2nd edition: 307–336, 2003.

    Google Scholar 

  5. Dorr RT: Pharmacologic management of vesicant -chemotherapy extravasations. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton & Lange, 2nd edition: 109–118, 1994.

    Google Scholar 

  6. Gain M, Melzer S, Meyer-Jürshof A, et al: Daunorubicin: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch, Pharmazeutisch-wissenschaftliche Monographien. Verlag Heiner Biller, vol 5: 27–28, 2001.

    Google Scholar 

  7. Stanley A: Managing complications of chemotherapy administration. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 4th edition: 119–193, 2002.

    Google Scholar 

  8. Mullin S, Beckwith MC, Tyler LS: Prevention and management of antineoplastic extravasation injury. Hosp Pharm 35: 57–76, 2000.

    Google Scholar 

  9. Kraft A, Weinig S, Edinger M, et al: Anthrazyklin-Extravasate. Der Onkologe 6: 674–686, 2000.

    Article  Google Scholar 

  10. Cox RF: Managing skin damage induced by doxorubicin hydrochloride and daunorubicin hydrochloride. Am J Hosp Pharm 41: 2410–2414, 1984.

    PubMed  CAS  Google Scholar 

  11. Dorr RT: Antidotes to vesicant chemotherapy extravasations. Blood Rev 4: 41–60, 1990.

    Article  PubMed  CAS  Google Scholar 

  12. Schneider SM, Distelhorst CW: Chemotherapy-induced emergencies. Semin Oncol 16: 572–578, 1989.

    PubMed  CAS  Google Scholar 

  13. Gain M, Melzer S, Meyer-Jürshof A, et al: Daunorubicin: Nebenwirkungen. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch, Pharmazeutisch-wissenschaftliche Monographien. Verlag Heiner Biller, vol 5: 14, 2001.

    Google Scholar 

  14. Summary of product characteristics Daunoblastin® (Germany), Pharmacia, March 2004.

    Google Scholar 

  15. Jordan K, Grothe W, Schmoll HJ: Paravasation von Zytostatika: Prävention und Therapie. Dtsch Med Wochenschr 130: 33–37, 2005.

    Article  PubMed  CAS  Google Scholar 

  16. Krämer I, Stützle M: Zytostatika-Paravasation – Wie ist vorzugehen? Krankenhauspharmazie 23: 261–268, 2002.

    Google Scholar 

  17. Ener RA, Meglathery SB, Styler M: Extravasation of systemic hemato-oncological therapies. Ann Oncol 15: 858–862, 2004.

    Article  PubMed  CAS  Google Scholar 

  18. Koppel RA, Boh EE: Cutaneous reactions to chemotherapeutic agents. Am J Med Sci 321: 327–335, 2001.

    Article  PubMed  CAS  Google Scholar 

  19. Alley E, Green R, Schuchter L: Cutaneous toxicities of cancer therapy. Curr Opin Oncol 14: 212–216, 2002.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. CRETA – Cancer Research & Trial Agency GmbH, Bad Sauerbrunn, Österreich

    Ines Mader MD

  2. Krankenhaus und Geriatriezentrum, SMZ Floridsdorf, Wien, Österreich

    Mag. pharm. Patrizia Fürst-Weger

  3. Klinische Abteilung für Onkologie, Univ.-Klinik für Innere Medizin I, Wien, Österreich

    Univ.-Prof. Dr. Robert Mader

  4. Anstaltsapotheke, Landeskrankenhaus – Universitätskliniken Innsbruck, Innsbruck, Österreich

    Mag. pharm. Dr. Elisabeth Nogler-Semenitz

  5. Apotheke LKH-Univ.-Klinikum Graz, Graz, Österreich

    Mag. pharm. Sabine Wassertheurer

Authors
  1. Ines Mader MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mag. pharm. Patrizia Fürst-Weger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Univ.-Prof. Dr. Robert Mader
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mag. pharm. Dr. Elisabeth Nogler-Semenitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mag. pharm. Sabine Wassertheurer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag/Wien

About this chapter

Cite this chapter

Mader, I., Fürst-Weger, P., Mader, R., Nogler-Semenitz, E., Wassertheurer, S. (2010). Daunorubicin. In: Extravasation of Cytotoxic Agents. Springer, Vienna. https://doi.org/10.1007/978-3-211-88893-3_26

Download citation

  • DOI: https://doi.org/10.1007/978-3-211-88893-3_26

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-88889-6

  • Online ISBN: 978-3-211-88893-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation